ClinicalTrials.gg
CompletedNCT02268773Updated Oct 20, 2014

Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers

A Phase 1 interventional study of Asasantin® and Acetylsalicylic acid low dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-20.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

To compare the combination of acetylsalicylic acid (25 mg) + modified-release dipyridamole (200 mg) bd versus acetylsalicylic acid (75 mg dispersible tablet once daily) in its effect on inhibition of thromboxane B2 formation

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female healthy volunteers aged 20 to 50 years
  • Clinically normal medical history
  • Clinically normal findings on physical examination
  • Capable of comprehending and communicating effectively with the investigator and staff and of providing
  • Willing to give informed consent prior to participation in the trial (i.e. prior to any trial-specific procedures)

Exclusion criteria

Exclusion Criteria:

  • Any disease. (A significant disease is defined as a disease which in the opinion of the investigator may either put the subject at risk because of participation in the study or a disease which may influence the results of the study or the subject's ability to participate in the study)
  • Clinically significant abnormal baseline haematology, blood chemistry or urinalysis findings
  • Serum glutamate-oxaloacetate transferase () or serum glutamate-pyruvate transferase (SGPT) > 80 IU/L, > 34 µmol/L or creatinine > 176 µmol/L regardless of clinical condition. Repeat laboratory evaluation will not be conducted in these subjects
  • Use of dipyridamole, aspirin or any non-steroidal anti-inflammatory agent (NSAID) during the previous two weeks
  • Active peptic ulceration or history of peptic ulcer disease
  • Known history of or suspected to dipyridamole, aspirin, any NSAID or any other component of the test drugs
  • History of any bleeding disorders
  • History of cerebral haemorrhage
  • Resting, seated blood pressure less than 90/60 mmHg
  • Participation in any drug clinical trial within sixteen weeks prior to the start of the trial
  • Any indication of current or previous abuse of alcohol, solvents or drugs
  • Any chronic illness
  • Asthma
  • Requirement for any other medication one month before or during the study
  • Pregnant or nursing women or women of not using a medically approved means of (e.g. oral contraceptives, intrauterine devices or surgically sterile) were to be excluded
  • Previous participation in the randomisation phase of this clinical trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Acetylsalicylic acid low dose with Asasantin®

    Drug: Asasantin® · Drug: Acetylsalicylic acid low dose

  • Active comparator
    Acetylsalicylic acid high dose

    Drug: Acetylsalicylic acid high dose

Interventions

  • DrugAsasantin®

    Also known as: modified-release dipyridamole

  • DrugAcetylsalicylic acid low dose
  • DrugAcetylsalicylic acid high dose
06

What researchers measure

Primary outcomes

  1. Absolute serum thromboxane B2 level

    Time frame: At day 3 after start of drug administration

Secondary outcomes

  1. Change in platelet aggregation

    measured ex-vivo

    Time frame: At day 3 after start of drug administration

  2. Change in time course of inhibition of serum thromboxane B2

    Time frame: Pre-dose, up to day 14 after start of drug administration

  3. Change in time course of inhibition of platelet aggregation

    Time frame: Pre-dose, up to day 14 after start of drug administration

  4. Changes from baseline in vital signs

    systolic and diastolic blood pressure, pulse rate

    Time frame: Pre-dose, up to 14 days after first drug administration

  5. Changes from baseline in laboratory tests

    Time frame: Pre-dose, up to 14 days after first drug administration

  6. Changes from baseline in physical examination

    Time frame: Pre-dose, up to 14 days after first drug administration

  7. Changes from baseline in 12-lead ECG

    Time frame: Pre-dose, up to 14 days after first drug administration

  8. Number of patients with adverse events

    Time frame: Up to 14 days after start of drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2000 and a primary completion of May 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2014
First posted
Oct 20, 2014
Start
Jan 2000
Primary completionActual
May 2000
Last update
Oct 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02268773
Responsible party
Sponsor
First posted
Oct 20, 2014
Start date
Jan 2000
Primary completion
May 2000
Last update
Oct 20, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion